MK-677 never touches IGF-1 directly — yet it’s one of the most reliable ways to raise it. The increase is entirely second-hand: MK677 raises growth hormone, and growth hormone tells your liver to make IGF-1. Follow that chain and you understand both why the IGF-1 rise is so consistent and why it carries the caveats it does.
Below, we trace the pathway from MK-677 to IGF-1, what the human trials measured, and why this particular hormone matters so much.
Key Takeaways
MK-677 raises IGF-1 indirectly — by first raising growth hormone (GH), which then drives IGF-1 production.
The IGF-1 itself is made mostly in the liver, in response to GH.
In trials, MK-677 raised IGF-1 by roughly 40–90%, into the young-adult range.
The rise builds over about two weeks and is sustained with continued dosing.
IGF-1 mediates many of GH’s growth effects — which is why it’s the marker researchers track.
Caveat: chronically high IGF-1 carries debated long-term concerns, including a cancer association.
The pathway: MK-677 → GH → IGF-1
IGF-1 (insulin-like growth factor 1) sits one step downstream of growth hormone. The chain runs:
MK-677 activates the ghrelin receptor (GHSR-1a) and triggers your pituitary to release more growth hormone (mechanism overview).
That GH circulates and binds growth hormone receptors on the liver.
The liver responds by producing and secreting IGF-1 into the bloodstream.
So MK-677 doesn’t raise IGF-1 by acting on it — it raises GH, and GH does the rest. IGF-1 is the end of the relay, not the start.
Why GH and IGF-1 rise together
This is why you almost never see one without the other. Growth hormone is the signal; IGF-1 is much of the message being carried out. Many of the body-composition and tissue effects attributed to “growth hormone” are actually mediated by the IGF-1 that GH stimulates.
That’s also why IGF-1 is the marker researchers measure. GH is released in short pulses and is hard to capture in a single blood draw; IGF-1 is more stable and reflects the average GH activity over time. A rising IGF-1 is the clean, readable signature that MK-677 is doing its job.
Step
What happens
Simple explanation
1. Oral intake
MK-677 is taken orally and absorbed into the bloodstream.
It does not need to be injected like growth hormone.
2. Ghrelin receptor activation
MK-677 activates the growth hormone secretagogue receptor, known as GHS-R1a.
It mimics ghrelin, the body’s “hunger hormone”.
3. Pituitary stimulation
The pituitary gland releases more growth hormone.
MK-677 encourages the body to produce more of its own GH.
4. GH reaches the liver
Growth hormone travels through the blood to the liver.
The liver is one of the main sites where IGF-1 is produced.
5. IGF-1 production rises
The liver produces and releases more IGF-1.
This is the key reason MK-677 is associated with higher IGF-1 levels.
6. IGF-1 circulates
IGF-1 enters the bloodstream and reaches tissues around the body.
IGF-1 acts as a downstream signal from growth hormone.
What makes the IGF-1 finding credible isn’t one study — it’s that several controlled trials, in different populations, at different durations, all show the same thing. Here’s what each measured.
Healthy young men (short-term, dose-ranging). The clearest dose-response data comes from a 7-day, randomised, double-blind, placebo-controlled crossover study in healthy young men comparing 5 mg and 25 mg of MK-677 against placebo (Copinschi et al., 1996). IGF-1 rose dose-dependently — the higher dose produced the larger increase — establishing that the effect scales with dose rather than being all-or-nothing.
The durability test (two years). Short studies can’t tell you whether the body simply adapts and the effect fades. The landmark answer came from a two-year, randomised, double-blind, placebo-controlled trial in 65 healthy adults aged 60–81 taking daily MK-677 (Nass et al., 2008). IGF-1 rose to young-adult levels and stayed elevated across the full two years, and the GH/IGF-1 increase was accompanied by a measurable gain in fat-free mass (about 1.6 kg vs placebo) — confirming the hormone change translated into a real physiological effect, not just a number on a lab report.
Putting the numbers together. Across these trials the IGF-1 increase lands roughly in the 40–90% range, depending on dose, age, and baseline (people starting lower, like older adults, tend to show the largest relative rise). Two consistent patterns stand out:
It builds, it doesn’t spike. IGF-1 climbs over roughly two weeks rather than appearing overnight — because it takes sustained GH stimulation to ramp up the liver’s IGF-1 output.
It holds. Rather than fading as the body adapts, the elevated IGF-1 was maintained over months and out to two years of continued dosing.
The breadth matters: the same effect shows up in young men, healthy elderly, and over both 7-day and 2-year windows. That consistency across populations and timeframes is why the IGF-1 response is considered one of MK-677’s most reliably documented actions.
Why the IGF-1 rise cuts both ways
The same IGF-1 increase that researchers find interesting is also the source of MK-677’s most-debated long-term concern. Chronically elevated IGF-1 has an epidemiological association with certain cancers (including prostate, breast, and colorectal).
Two honest caveats: that’s an association, not proof MK-677 causes cancer, and the trial IGF-1 levels were restored to a normal young-adult range, not pushed sky-high. But because no long-term human safety data exists for non-medical use, the IGF-1 elevation is best treated as an open question, not a settled one.
Does MK-677 raise IGF-1 directly? No. It raises growth hormone, and growth hormone stimulates the liver to produce IGF-1. The IGF-1 rise is a downstream effect.
How long does it take to raise IGF-1? In trials, IGF-1 climbed over about two weeks and reached the young-adult range within two to four weeks of daily dosing.
Is a higher IGF-1 a good thing? It depends on the context. IGF-1 mediates many of GH’s effects, but chronically high IGF-1 carries debated long-term risks. Higher isn’t automatically better.
Does the IGF-1 increase last? Yes — in trials it stayed elevated over months to two years of continued dosing.
The bottom line
MK-677 increases IGF-1 indirectly: it raises growth hormone, and growth hormone drives the liver to produce IGF-1. The result is a consistent, sustained rise into the young-adult range — which is exactly why IGF-1 is the marker that tracks MK-677’s activity, and also why its long-term safety question centres on that same hormone.
For anyone studying MK-677 in a research setting, it’s unapproved and frequently counterfeited, so third-party purity testing (HPLC and mass spectrometry) is the only reliable way to confirm what’s in a vial. For any decision beyond research, consult a qualified healthcare professional.
This article is for informational and educational purposes only and is not medical advice. MK-677 is not approved for human use. Always consult a qualified healthcare professional.
Nass et al. (2008), oral ghrelin mimetic (MK-677) in healthy older adults, Annals of Internal Medicine (PMC2757071): https://pmc.ncbi.nlm.nih.gov/articles/PMC2757071/
Chapman et al. (1996), daily oral MK-677 stimulates the GH/IGF-I axis in healthy elderly, JCEM 81(12):4249: https://academic.oup.com/jcem/article-abstract/81/12/4249
Copinschi et al. (1996), 7-day MK-677 on 24-hour GH, IGF-I and adrenocortical function, JCEM: https://doi.org/10.1210/jcem.81.8.8768828
IGF-1 and cancer risk — meta-analysis across 96 studies (PMC2987015): https://pmc.ncbi.nlm.nih.gov/articles/PMC2987015/
Nick Taylor
Nick Paul Taylor is an experienced life sciences journalist and biopharma writer with a background in biology and healthcare innovation.
Over the past 15 years, he has covered key developments in pharmaceutical research, biotechnology, drug regulation, and medical technology, writing for leading industry publications.
Nick’s reporting focuses on translating complex clinical data, FDA updates, and biotech trends into accessible insights for professionals across the pharma and medtech sectors.
Follow Nick for expert analysis on biopharma pipelines, regulatory news, and emerging healthcare technologies.
Current Legal Status In the UK, SARMs (Selective Androgen Receptor Modulators) are not licensed medicines. The MHRA (Medicines and Healthcare products Regulatory Agency) has never approved them for human use. As a result, they cannot be marketed as “supplements” or sold as treatments. “SARMs are not authorised medicines in the UK and therefore cannot legally …
Key Takeaways You’ve probably seen this question asked everywhere – Reddit threads, research forums, even gym locker rooms: Whether you’re designing a compliant research protocol, preparing for bloodwork, or just trying to understand metabolic timelines, the answer is more complex than you might think. Let’s break it down by compound, half-life, detection methods, and the …
Are the SARMs you’re using really what they claim to be? In an industry flooded with underdosed, mislabeled, or outright fake compounds, knowing how to verify SARMs quality is critical – especially for researchers who rely on consistency, purity, and safety. Here’s your step-by-step checklist to ensure you’re working with legitimate, research-grade SARMs. Key Takeaways …
To save you reading all the small print, we’ve reviewed and summarised the research about MK677 Study 1: Nass R, et al. (2008) Title: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trialLink: PubMed Summary This randomized, double-blind, placebo-controlled trial evaluated the long-term effects (12 …
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
How Does MK-677 Increase IGF-1?
MK-677 never touches IGF-1 directly — yet it’s one of the most reliable ways to raise it. The increase is entirely second-hand: MK677 raises growth hormone, and growth hormone tells your liver to make IGF-1. Follow that chain and you understand both why the IGF-1 rise is so consistent and why it carries the caveats it does.
Below, we trace the pathway from MK-677 to IGF-1, what the human trials measured, and why this particular hormone matters so much.
Key Takeaways
The pathway: MK-677 → GH → IGF-1
IGF-1 (insulin-like growth factor 1) sits one step downstream of growth hormone. The chain runs:
So MK-677 doesn’t raise IGF-1 by acting on it — it raises GH, and GH does the rest. IGF-1 is the end of the relay, not the start.
Why GH and IGF-1 rise together
This is why you almost never see one without the other. Growth hormone is the signal; IGF-1 is much of the message being carried out. Many of the body-composition and tissue effects attributed to “growth hormone” are actually mediated by the IGF-1 that GH stimulates.
That’s also why IGF-1 is the marker researchers measure. GH is released in short pulses and is hard to capture in a single blood draw; IGF-1 is more stable and reflects the average GH activity over time. A rising IGF-1 is the clean, readable signature that MK-677 is doing its job.
Read more : HGH vs MK677
What the trials measured
What makes the IGF-1 finding credible isn’t one study — it’s that several controlled trials, in different populations, at different durations, all show the same thing. Here’s what each measured.
Healthy young men (short-term, dose-ranging). The clearest dose-response data comes from a 7-day, randomised, double-blind, placebo-controlled crossover study in healthy young men comparing 5 mg and 25 mg of MK-677 against placebo (Copinschi et al., 1996). IGF-1 rose dose-dependently — the higher dose produced the larger increase — establishing that the effect scales with dose rather than being all-or-nothing.
The durability test (two years). Short studies can’t tell you whether the body simply adapts and the effect fades. The landmark answer came from a two-year, randomised, double-blind, placebo-controlled trial in 65 healthy adults aged 60–81 taking daily MK-677 (Nass et al., 2008). IGF-1 rose to young-adult levels and stayed elevated across the full two years, and the GH/IGF-1 increase was accompanied by a measurable gain in fat-free mass (about 1.6 kg vs placebo) — confirming the hormone change translated into a real physiological effect, not just a number on a lab report.
Putting the numbers together. Across these trials the IGF-1 increase lands roughly in the 40–90% range, depending on dose, age, and baseline (people starting lower, like older adults, tend to show the largest relative rise). Two consistent patterns stand out:
The breadth matters: the same effect shows up in young men, healthy elderly, and over both 7-day and 2-year windows. That consistency across populations and timeframes is why the IGF-1 response is considered one of MK-677’s most reliably documented actions.
Why the IGF-1 rise cuts both ways
The same IGF-1 increase that researchers find interesting is also the source of MK-677’s most-debated long-term concern. Chronically elevated IGF-1 has an epidemiological association with certain cancers (including prostate, breast, and colorectal).
Two honest caveats: that’s an association, not proof MK-677 causes cancer, and the trial IGF-1 levels were restored to a normal young-adult range, not pushed sky-high. But because no long-term human safety data exists for non-medical use, the IGF-1 elevation is best treated as an open question, not a settled one.
Further reading : MK677 Side Effects
Frequently asked questions
Does MK-677 raise IGF-1 directly?
No. It raises growth hormone, and growth hormone stimulates the liver to produce IGF-1. The IGF-1 rise is a downstream effect.
How long does it take to raise IGF-1?
In trials, IGF-1 climbed over about two weeks and reached the young-adult range within two to four weeks of daily dosing.
Is a higher IGF-1 a good thing?
It depends on the context. IGF-1 mediates many of GH’s effects, but chronically high IGF-1 carries debated long-term risks. Higher isn’t automatically better.
Does the IGF-1 increase last?
Yes — in trials it stayed elevated over months to two years of continued dosing.
The bottom line
MK-677 increases IGF-1 indirectly: it raises growth hormone, and growth hormone drives the liver to produce IGF-1. The result is a consistent, sustained rise into the young-adult range — which is exactly why IGF-1 is the marker that tracks MK-677’s activity, and also why its long-term safety question centres on that same hormone.
For anyone studying MK-677 in a research setting, it’s unapproved and frequently counterfeited, so third-party purity testing (HPLC and mass spectrometry) is the only reliable way to confirm what’s in a vial. For any decision beyond research, consult a qualified healthcare professional.
This article is for informational and educational purposes only and is not medical advice. MK-677 is not approved for human use. Always consult a qualified healthcare professional.
Sources
Nick Taylor
Nick Paul Taylor is an experienced life sciences journalist and biopharma writer with a background in biology and healthcare innovation. Over the past 15 years, he has covered key developments in pharmaceutical research, biotechnology, drug regulation, and medical technology, writing for leading industry publications. Nick’s reporting focuses on translating complex clinical data, FDA updates, and biotech trends into accessible insights for professionals across the pharma and medtech sectors. Follow Nick for expert analysis on biopharma pipelines, regulatory news, and emerging healthcare technologies.
Related Posts
Are SARMs Legal to Buy in the UK for Research Purposes?
Current Legal Status In the UK, SARMs (Selective Androgen Receptor Modulators) are not licensed medicines. The MHRA (Medicines and Healthcare products Regulatory Agency) has never approved them for human use. As a result, they cannot be marketed as “supplements” or sold as treatments. “SARMs are not authorised medicines in the UK and therefore cannot legally …
How Long Do SARMs Stay In Your System? What the New Research Says (Case Study)
Key Takeaways You’ve probably seen this question asked everywhere – Reddit threads, research forums, even gym locker rooms: Whether you’re designing a compliant research protocol, preparing for bloodwork, or just trying to understand metabolic timelines, the answer is more complex than you might think. Let’s break it down by compound, half-life, detection methods, and the …
How to Verify SARMs Quality in 10 Steps (A Researcher’s Checklist)
Are the SARMs you’re using really what they claim to be? In an industry flooded with underdosed, mislabeled, or outright fake compounds, knowing how to verify SARMs quality is critical – especially for researchers who rely on consistency, purity, and safety. Here’s your step-by-step checklist to ensure you’re working with legitimate, research-grade SARMs. Key Takeaways …
Checking the research on MK-677
To save you reading all the small print, we’ve reviewed and summarised the research about MK677 Study 1: Nass R, et al. (2008) Title: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trialLink: PubMed Summary This randomized, double-blind, placebo-controlled trial evaluated the long-term effects (12 …